title: Targeted drugs and Psycho-oncological intervention for breast cancer patients.
abstract: Personalized medicine is a new field based on molecular biology and genomics in which targeted tumor therapies are administered to patients. Psycho-oncology is a complementary approach that considers social and psychological aspects of patients as part of the treatments for cancer patients. The aim of this mini-review is to weigh clinical benefits for breast cancer patients of both treatments and possibly enhance benefits by modulating the use of both interventions. We have compared and evaluated on the one hand the use of anti Vascular Endothelial Growth Factor and, on the other hand, psycho-oncological interventions in metastatic and non-metastatic breast cancer patients.Both treatments did not increase survival of metastatic breast cancer patients, while in a selected study psycho-oncological interventions extended lifespan of non-metastatic breast cancer patients and ameliorate psychological and social factors of metastatic breast cancer patients. Because the two approaches address completely different aspects of cancer patients, if the comparison is limited to the extension of survival, the value of these two treatments cannot be assessed and compared.It is likely that by comparing patients reported outcomes, possibly by using standardized Quality of Life questionnaires, both patients and health care providers can weigh the benefits of the two treatments. It is therefore important to evaluate the use of cancer patients' quality of life measures as a mean to improve their experiences about life and treatment, and possibly to extend their survival.
authors.affiliation: Department of Psychology, Freie Universität Berlin, Hittorfstr. 16, 14195, Berlin, Deutschland. flavio.dabramo@fu-berlin.de.
authors.forename: Flavio
authors.initials: F
authors.lastname: D'Abramo
authors.affiliation: Charité Comprehensive Cancer Center, Charitéplatz 1, 10117, Berlin, Deutschland.
authors.forename: Ute
authors.initials: U
authors.lastname: Goerling
authors.affiliation: Department of Environment and Primary Prevention, Italian National Institute of Health, ISS, V.le Regina Elena 299, 00161, Rome, Italy.
authors.forename: Cecilia
authors.initials: C
authors.lastname: Guastadisegni
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000068258:Bevacizumab / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000523:psychology*; D003863:Depression / Q000209:etiology; D005260:Female; D006801:Humans; D057285:Precision Medicine; D011788:Quality of Life; D016019:Survival Analysis
chemical_list: D000970:Antineoplastic Agents; D000068258:Bevacizumab
keywords: Avastin; Bevacizumab; Breast cancer; Cancer targeted drugs; Psycho-oncological intervention; Psychological intervention; Quality of life; Segt; Vascular endothelial growth factor (VEGF)